Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 4;13(9):e070848.
doi: 10.1136/bmjopen-2022-070848.

Understanding Heterogeneity in Patients' Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis

Affiliations

Understanding Heterogeneity in Patients' Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis

Betty Hsiao et al. BMJ Open. .

Abstract

Objective: Uptake of treat-to-target (TTT) strategies for rheumatoid arthritis (RA) management is low. Our objective was to understand the heterogeneity in patients' conceptualisation of RA treatment to inform interventions improving TTT uptake.

Design: Eligible participants recruited from an online research registry rated 56 items (on 5-point scales) reflecting concepts raised from patient interviews. Using items describing adhering to physician recommendations to create a binary criterion variable for medication adherence, we conducted a principal components analysis on the remaining items using Varimax rotation, describing how these factors predict adherence over and above demographic characteristics. We further use optimal sets in regression to identify the individual concepts that are most predictive of medication adherence.

Results: We found significant heterogeneity in patients' conceptualisation of RA treatment among 621 persons with RA. A scree plot revealed a four-factor solution explained 38.4% of the variance. The four factors expected to facilitate TTT uptake were (% variance explained): (1) Access to high quality care and support (11.3%); (2) low decisional conflict related to changing disease-modifying antirheumatic drugs (DMARDs) (10.1%); (3) endorsement of a favourable DMARD risk/benefit ratio (9.9%); and (4) confidence that testing reflects disease activity (7.2%). These factors account for 13.8% of the variance in full medication adherence, fully explaining the only significant demographic predictor, age of the patient. The individual items most predictive of poor adherence centre on the lack of effective patient-physician communication, specifically insufficient access to information from rheumatologists, along with the need to seek information elsewhere.

Conclusion: Patients' conceptualisation of RA treatment varies; however, almost all patients have difficulty escalating DMARDs, even with access to quality information and an understanding of the benefits of TTT. Tailored interventions are needed to address patient hesitancy to escalate DMARDs.

Keywords: QUALITATIVE RESEARCH; RHEUMATOLOGY; Rheumatology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JRC: received research funding from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, Janssen, Lilly, Novartis, Myriad, Pfizer, Sanofi, Setpoint, Schipher, UCB and served as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Corevitas, Janssen, Lilly, Novartis, Myriad, Pfizer, Sanofi, Setpoint, Schipher, UCB. LH: employee and shareholder of CorEvitas LLC; a consultant to AbbVie, Bristol Myers Squibb and Roche; speakers bureau for Bristol Myers Squibb.

Similar articles

References

    1. Harrold LR, Harrington JT, Curtis JR, et al. . Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American college of rheumatology treatment recommendations. Arthritis Rheum 2012;64:630–8. 10.1002/art.33380 - DOI - PMC - PubMed
    1. Zak A, Corrigan C, Yu Z, et al. . Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. Rheumatology (Oxford) 2018;57:1933–7. 10.1093/rheumatology/key179 - DOI - PMC - PubMed
    1. Solomon DH, Losina E, Lu B, et al. . Implementation of treat-to-target in rheumatoid arthritis through a learning collaborative: results of a randomized controlled trial. Arthritis Rheumatol 2017;69:1374–80. 10.1002/art.40111 - DOI - PMC - PubMed
    1. Stoffer MA, Schoels MM, Smolen JS, et al. . Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis 2016;75:16–22. 10.1136/annrheumdis-2015-207526 - DOI - PMC - PubMed
    1. Harrold LR, Reed GW, John A, et al. . Cluster-randomized trial of a behavioral intervention to incorporate a treat-to-target approach to care of US patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018;70:379–87. 10.1002/acr.23294 - DOI - PMC - PubMed

Publication types

Substances